Travere Therapeutics, Inc. is rated Buy with FILSPARI’s robust growth, FDA approval, and key milestones ahead. Click here to ...

Travere Therapeutics (TVTX) stock climbs as the FDA skips advisory meeting in the review of a label expansion for the company ...

Travere Therapeutics TVTX announced that the FDA, following further review of the supplemental new drug application (sNDA) ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that following further review of the supplemental New Drug ...

Travere Therapeutics (TVTX) has witnessed significant developments, including the FDA's decision not to call an advisory committee meeting for the sNDA of FILSPARI®, while the drug is still under ...

An announcement from Travere Therapeutics ( ($TVTX) ) is now available. On September 10, 2025, Travere Therapeutics announced that the FDA has ...

Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Travere Therapeutics, Inc. (TVTX) shares are trading higher on Wednesday after the company announced that it was informed by ...

The update now reduces the frequency of liver function monitoring to every 3 months from the onset of treatment. The Food and Drug Administration (FDA) has updated the risk evaluation and mitigation ...

FDA cuts liver monitoring for Filspari to every three months and drops embryo-fetal toxicity REMS. Travere awaits FDA’s 2026 decision on Filspari for FSGS. Get the data-driven signals to profit from ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has approved updated Risk Evaluation and Mitigation Strategy (REMS) labeling for FILSPARI ® ...